A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin.
| Autor: | Cosso F; Department of Health Sciences, University of Florence., Roviello G; Department of Health Sciences, University of Florence., Catalano M; Department of Health Sciences, University of Florence., Botteri C; Department of Health Sciences, University of Florence., Comin CE; Pathological Histology and Molecular Diagnostics Unit, Careggi University Hospital., Castiglione F; Pathological Histology and Molecular Diagnostics Unit, Careggi University Hospital., Ferrari K; Respiratory Medicine Unit, Careggi University Hospital, Florence., Baldini E; Department of Medical Oncology, San Luca Hospital, Lucca, Italy., Mini E; Department of Health Sciences, University of Florence. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Anti-cancer drugs [Anticancer Drugs] 2024 Jan 01; Vol. 35 (1), pp. 76-80. Date of Electronic Publication: 2023 Mar 10. |
| DOI: | 10.1097/CAD.0000000000001517 |
| Abstrakt: | Lung cancer is the malignancy with the highest morbidity and mortality worldwide. Approximately 60% of non-small cell lung cancer (NSCLC) presents driver alterations most of which are targetable. Nowadays, limited clinical data are available regarding the efficacy of epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with NSCLC harboring uncommon EGFR mutations, considering their heterogeneity. Herein, we report a rare case of EGFR-mutated lung adenocarcinoma which has developed into squamous cell carcinoma with uncommon EGFR (Ex18) compound mutations and phosphatidylinositol 3-kinase mutation receiving afatinib at the forefront. (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|